- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00812305
Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects
September 3, 2010 updated by: Pacira Pharmaceuticals, Inc
A Randomized, Double-Blind, Phase 1 Study to Assess the Pharmacokinetics and Safety of SKY0402 in Subjects With Impaired Hepatic Function
Review differences between how a healthy person and how a person with liver problems handles the study drug.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Evaluate the pharmacokinetic (PK) profile of SKY0402 in subjects with moderate hepatic impairment compared with age-, gender-, and weight-matched control subjects with normal hepatic function.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Warsaw, Poland
- MTZ Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All Subjects:
- Male or female, ages 18-65 years, inclusive, at Screening. Eligible female subjects of childbearing potential with a nonsterilized male sexual partner must agree to use a hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device beginning >30 days prior to study drug administration and continuing until >7 days after the end of the study. Female subjects who are postmenopausal must have been postmenopausal for >1 year if they wish not to use contraceptives. If postmenopausal status is questionable, the subject's follicle stimulating hormone (FSH) level must be checked and must be elevated and consistent with postmenopausal levels (i.e., >40 IU/L); otherwise these subjects must agree to use contraceptives listed above.
- Able and willing to comply with all study visits and procedures, including returning as scheduled for post-treatment visits.
- Able to speak, read, and understand the language of the informed consent, and any other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to study assessments.
- Willing and capable of providing written informed consent.
Subjects with Hepatic Impairment:
- Subjects must have a positive diagnosis of liver cirrhosis (hepatic fibrosis with evidence of either micro- or macro-nodular regeneration) that has been stable for two months and is confirmed by imaging techniques, biopsy, or physical signs consistent with a clinical diagnosis of liver cirrhosis (e.g., liver firmness to palpation, splenic enlargement, spider angiomata, palmar erythema, parotid hypertrophy, testicular atrophy, gynecomastia).
- Subjects must have an impaired but stable hepatic function evidenced by Child-Pugh Clinical Assessment Score between 7 and 9 at both screening and baseline.
Control Subjects with Normal Hepatic Function:
- Subjects must be in general good health as determined by past medical history, physical examination, vital signs, electrocardiogram, Chest X-Ray (CXR), and laboratory tests at screening.
- Subjects should be matched to a hepatically impaired subject in gender, age (±15%) and weight (±20%).
Exclusion Criteria:
All Subjects
- A history of hypersensitivity to amide type local anesthetics.
- Pregnancy, nursing, or planning to become pregnant during the course of the study.
- Body weight less than 60 kg (~132 lbs) or more than 120 kg (~264 lbs).
- BMI of less than 18 or more than 35 kg/m2
- Significant acute, new onset illness (e.g., flu, gastroenteritis) within two weeks prior to study treatment administration.
- Clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, neurological, or psychiatric disease that may pose a significant safety risk or diminish subject's ability to undergo all study procedures and assessments
- History of immunocompromised status, including a positive HIV (ELISA and Western blot) test result.
- Evidence of active alcohol or drug abuse as indicated by the tests conducted during the screening or baseline evaluations; subject must state they are willing to remain alcohol and drug free for three weeks after study drug administration.
- Use of ASA within 10 days prior to study drug administration.
- Use of Lidocaine, mepivacaine, etidocaine, ropivacaine, and any amide-type anesthetics in any form within 5 elimination half-lives.
- Use of any local anesthetic within 3 days prior to study drug administration.
- Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
- Any condition that, in the opinion of the Investigator, renders a subject unsuitable for participation in the study. NOTE: A specific rationale must be provided and documented for excluding all prospective subjects deemed unsuitable for the study.
Subjects with Hepatic Impairment:
- Clinically significant abnormal findings other than hepatic impairment.
- Clinical evidence of severe ascites, as judged by the investigator.
- History of surgical portosystemic shunt.
- Fluctuating or rapidly deteriorating hepatic function as indicated by recent history or by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
- On active Hepatitis treatment with Interferon or other excluded medications (see Appendix 4)
Control Subjects with Normal Hepatic Function:
- Prohibited prescription medications within 14 days prior to dosing; see Appendix 4 for specific medications.
- History or presence of liver disease or liver injury as indicated by an abnormal liver function profile such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin.
- Hepatitis B as indicated by positive HBs Ag, or Hepatitis C as indicated by positive anti-HCV result.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose in healthy patients
|
SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
Other Names:
|
Experimental: Low dose in hepatically impaired patients
|
SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum plasma concentration of SKY0402
Time Frame: Multiple through 96 hours
|
Multiple through 96 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janusz Rupinski, Pharm-Olam International Polska
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
August 1, 2009
Study Registration Dates
First Submitted
December 9, 2008
First Submitted That Met QC Criteria
December 18, 2008
First Posted (Estimate)
December 22, 2008
Study Record Updates
Last Update Posted (Estimate)
September 8, 2010
Last Update Submitted That Met QC Criteria
September 3, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SKY0402C110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on SKY0402 300mg in healthy patients
-
Postgraduate Institute of Dental Sciences RohtakCompleted
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoUnknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingDiabetes Mellitus, Type 2France
-
Daewoong Pharmaceutical Co. LTD.RecruitingGastric CancerKorea, Republic of
-
Postgraduate Institute of Dental Sciences RohtakUnknown
-
Nadia Bouzidi, PhDUnknown
-
Weill Medical College of Cornell UniversityNovartis PharmaceuticalsTerminatedBleeding | Thrombocytopenia | Wiskott-Aldrich SyndromeUnited States
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
University of Alabama at BirminghamActive, not recruiting